Informações:
Falhas:
ID
33558
Descrição
Study to Evaluate Real-world Pharmacoeconomics and Resistance Mechanisms of Panitumumab in Metastatic Colorectal Cancer Patients; ODM derived from: https://clinicaltrials.gov/show/NCT02135757
Link
https://clinicaltrials.gov/show/NCT02135757
Palavras-chave
Versões (1)
- 13/12/2018 13/12/2018 -
Titular dos direitos
See clinicaltrials.gov
Transferido a
13 de dezembro de 2018
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Colorectal Cancer Metastatic NCT02135757
Eligibility Colorectal Cancer Metastatic NCT02135757
- StudyEvent: Eligibility
Similar models
Eligibility Colorectal Cancer Metastatic NCT02135757
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Secondary malignant neoplasm of large intestine
Item
patients with a histologically confirmed diagnosis of mcrc.
boolean
C0346973 (UMLS CUI [1])
Epidermal Growth Factor Receptor Expression Immunohistochemistry
Item
immunohistochemical evidence of egfr expression.
boolean
C0034802 (UMLS CUI [1,1])
C0597360 (UMLS CUI [1,2])
C0021044 (UMLS CUI [1,3])
C0597360 (UMLS CUI [1,2])
C0021044 (UMLS CUI [1,3])
ECOG performance status
Item
ecog performance status of 0, 1 or 2.
boolean
C1520224 (UMLS CUI [1])
Chemotherapy refractory | fluoropyrimidine | oxaliplatin | irinotecan
Item
patients refractory to fluoropyrimidine, oxaliplatin, and irinotecan chemotherapy regimens
boolean
C0392920 (UMLS CUI [1,1])
C0205269 (UMLS CUI [1,2])
C0596581 (UMLS CUI [2])
C0069717 (UMLS CUI [3])
C0123931 (UMLS CUI [4])
C0205269 (UMLS CUI [1,2])
C0596581 (UMLS CUI [2])
C0069717 (UMLS CUI [3])
C0123931 (UMLS CUI [4])
Patients KRAS wt Allele | panitumumab | Third line treatment Secondary malignant neoplasm of large intestine | Patients KRAS gene Mutated | Standard of Care Third line treatment Secondary malignant neoplasm of large intestine
Item
patients with a wt kras scheduled to receive panitumumab as a single agent for the third-line treatment of mcrc or patients with a mt kras scheduled to receive soc for third-line treatment of mcrc.
boolean
C0030705 (UMLS CUI [1,1])
C1705982 (UMLS CUI [1,2])
C0879427 (UMLS CUI [2])
C2986605 (UMLS CUI [3,1])
C0346973 (UMLS CUI [3,2])
C0030705 (UMLS CUI [4,1])
C1537502 (UMLS CUI [4,2])
C1705285 (UMLS CUI [4,3])
C2936643 (UMLS CUI [5,1])
C2986605 (UMLS CUI [5,2])
C0346973 (UMLS CUI [5,3])
C1705982 (UMLS CUI [1,2])
C0879427 (UMLS CUI [2])
C2986605 (UMLS CUI [3,1])
C0346973 (UMLS CUI [3,2])
C0030705 (UMLS CUI [4,1])
C1537502 (UMLS CUI [4,2])
C1705285 (UMLS CUI [4,3])
C2936643 (UMLS CUI [5,1])
C2986605 (UMLS CUI [5,2])
C0346973 (UMLS CUI [5,3])
Informed Consent
Item
signed and dated irb-approved informed consent document.
boolean
C0021430 (UMLS CUI [1])
Able to read English Language | Able to read French language | Comprehension English Language | Comprehension French language
Item
ability to read and understand english or french.
boolean
C0586740 (UMLS CUI [1,1])
C0376245 (UMLS CUI [1,2])
C0586740 (UMLS CUI [2,1])
C0376246 (UMLS CUI [2,2])
C0233733 (UMLS CUI [3,1])
C0376245 (UMLS CUI [3,2])
C0233733 (UMLS CUI [4,1])
C0376246 (UMLS CUI [4,2])
C0376245 (UMLS CUI [1,2])
C0586740 (UMLS CUI [2,1])
C0376246 (UMLS CUI [2,2])
C0233733 (UMLS CUI [3,1])
C0376245 (UMLS CUI [3,2])
C0233733 (UMLS CUI [4,1])
C0376246 (UMLS CUI [4,2])
Age
Item
18 years of age or older.
boolean
C0001779 (UMLS CUI [1])
Acquired Immunodeficiency Syndrome | Illness AIDS Related
Item
acquired immunodeficiency syndrome (aids-related illnesses) or known hiv disease.
boolean
C0001175 (UMLS CUI [1])
C0221423 (UMLS CUI [2,1])
C0001175 (UMLS CUI [2,2])
C0439849 (UMLS CUI [2,3])
C0221423 (UMLS CUI [2,1])
C0001175 (UMLS CUI [2,2])
C0439849 (UMLS CUI [2,3])